In this study, we show that an epirubicin/docetaxel‐induced increase in the blood levels of HMGB1 during the first days of neoadjuvant chemotherapy of early breast cancer correlates with the long‐term survival of patients. The gene discussed is HMGB1; the disease is breast carcinoma.